Reviews in Urology first launched in 1999 as a PubMed-indexed, quarterly journal featuring peer-reviewed research, case studies, thought leader interviews, and insights on emerging trends and research shaping the field of urology. New publisher, Specialty Networks, now plans to build on the journal’s long-standing focus on cutting-edge urology advances while offering expanded coverage of a broad range of urologic conditions and specialty care concerns.
Reviews in Urology, Specialty Networks’ flagship publication and the official journal of LUGPA, is designed to review the latest advances in the diagnosis and treatment of a wide range of urological conditions to help the busy, practicing urologist keep up to date with the rapidly evolving field of urology.
Reviews in Urology circulation is approximately all 10,000+ practicing urologists, including residents and fellows, in the United States.
View our mobile app for the best experience on your mobile device.
Interested in submitting your manuscript for consideration?
Want to reach a wider audience through the journal?
View articles from the latest issues.
I’m thrilled to share a recap of our successful March 2024 DC Fly-In, where LUGPA members gathered in Washington, DC, to advocate for the crucial health care reforms outlined in our 2024 Legislative and Regulatory Agenda.
The LUGPA board, in partnership with Specialty Networks, was thrilled to announce the return of Reviews in Urology in 2024, and no one more so than Specialty Networks’ CEO, Shailendra Sharma. “We are honored for our Reviews in Urology publication to be designated as the official journal of LUGPA and to further strengthen our partnership and commitment to LUGPA’s mission of preserving and advancing the independent practice of urology,” he said. Reviews in Urology first launched in 1999 as a PubMed-indexed, quarterly journal featuring peer-reviewed research, case studies, thought leader interviews, and insights on emerging trends and research shaping the field of urology. Mr Sharma says that Specialty Networks now plans to build on the journal’s long-standing focus on cutting-edge urology advances while offering expanded coverage of a broad range of urologic conditions and specialty care concerns. Mr Sharma sat down to talk with Neal Shore, MD, editor in chief of Reviews in Urology, to discuss the journal’s history and his hopes for the future of the journal and the profession.
Andrew J CohenRoss S LiaoErica SternJames E Wright
Urethral stricture disease (USD) is a progressive scar-forming disease commonly encountered by urologists and is challenging to manage. USD most frequently occurs in the bulbar urethra. Patients typically present with chronic obstructive voiding symptoms but may develop recurrent urinary tract infections, detrusor failure, or renal disease. The authors review the pathophysiology, diagnostic workup, and evidence-based management of bulbar urethral strictures (BUS). There are multiple surgical options to treat BUS. Endoscopic techniques (eg, dilation and urethrotomy) are suitable for the initial management of short strictures but new evidence-based guidelines recommend against repeated endoscopic treatment. Urethroplasty is the gold standard treatment for BUS of all lengths, with anastomotic techniques appropriate for strictures <2 cm and tissue substitution performed for longer strictures. New techniques, such as non-transecting urethroplasty, lack long-term data but may represent a paradigm shift in the field. Future treatments may utilize tissue-engineered grafts and agents that inhibit inflammation and scar formation. [Rev Urol. 2020;22(4):139–151] © 2021 MedReviews®, LLC
UrethroplastyBulbar urethral strictureUrethrotomyUrethral dilationBuccal graft non-transecting